Clinical trials
father daughter small banner

oNKord® is an NK-cell preparation for infusion currently in development for the treatment of hematologic malignancies and solid tumors. oNKord® phase II studies are scheduled for Q2 2020 for the diseases acute myeloid leukemia and multiple myeloma. Once clinical trial application has been approved; more information regarding recruitment and eligibility will be shared on this page.

Patients and healthcare professionals that are interested and would like to receive information upfront can contact us.

Completed clinical trials

Results of the AML oNKord® safety study is the baseline for application of oNKord® for all indications.

oNKord® - Acute Myeloid Leukemia – phase I

In collaboration with the Department of Hematology of the Radboud Medical Centre in Nijmegen (The Netherlands) a first in man study has been conducted using oNKord®. This HOVON-associated study was designed for elderly acute myeloid leukemia (AML) patients who were not eligible for allogeneic stem cell transplantation. Patients who had successfully achieved complete remission after chemotherapy were treated with oNKord®.

  • Ten elderly AML patients ineligible to receive allogeneic stem-cell transplantation (Allo-SCT) were treated with oNKord® following chemotherapy and fludarabine cyclophosphamide (Flu- Cy) conditioning
  • Confirmed that 100 billion NK-cells can be produced from one cord blood under GMP
  • Demonstrated no T-cell impurity
  • No dose limiting toxicities or Graft-versus-Host Disease (GVHD) observed in the study
  • oNKord® cells show in vivo survival, expansion and further maturation
  • oNKord® cells home to the bone marrow and target leukemia cells
  • Treatment with oNKord® resulted in strong reduction of residual disease as well as prolonged Progression-free Survival and Overall Survival as compared to historical data (1).
Elderly